# A Study of BR111 in Patients With Advanced Malignancies

> **NCT06937957** · PHASE1 · RECRUITING · sponsor: **BioRay Pharmaceutical Co., Ltd.** · enrollment: 166 (estimated)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** BR111 for Injection
- **DRUG:** BR111 for Injection

## Key facts

- **NCT ID:** NCT06937957
- **Lead sponsor:** BioRay Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-24
- **Primary completion:** 2027-10-09
- **Final completion:** 2027-12-31
- **Target enrollment:** 166 (ESTIMATED)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06937957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06937957, "A Study of BR111 in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06937957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*